An agent-based model of Epstein-Barr virus transmission and vaccination

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Epstein-Barr virus (EBV) infects over 90% of adults worldwide, causing infectious mononucleosis (IM) in adolescents and young adults and contributing to multiple malignancies. Despite its global burden, population-level transmission modeling of EBV remains limited. We present the first population-level agent-based model (ABM) of EBV transmission. The model is implemented with 10,000 agents and calibrated to age-specific seroprevalence data from the US National Health and Nutrition Examination Survey. Two complementary calibration methods are evaluated, each with its own distinct advantages: Approximate Bayesian Computation (ABC) and Bayesian Optimization with Expected Quantile Improvement (BO–EQI). ABC directly yields an approximate distribution of transmission parameters for propagation through vaccination scenarios. BO–EQI uses a limited simulation budget to identify well-fitting parameter vectors, particularly as the number of fitted parameters increases. We estimate parameter uncertainty at each resolution in a separate Gaussian-kernel posterior analysis, which requires additional simulations and an explicit model for discrepancies between simulated and observed prevalence. As an illustrative application, we simulate the population-level effect of hypothetical EBV vaccines over a 100-year projection horizon. Similar to a previous modeling study, our results suggest that vaccine durability is at least as critical as efficacy, and that a vaccine with direct protection against only EBV may persistently shift IM burden to older ages, an effect our longer simulation horizon reveals to be a durable equilibrium shift rather than a transient cohort phenomenon. These findings highlight the importance of careful vaccine target product profile design; in particular, our results suggest that dual efficacy against both EBV infection and IM progression represents the most promising achievable target profile, and should be a core design objective for next-generation EBV vaccines.

Article activity feed